parkinson.ca/promising-trea...
"Phase 3 DMT trials completing in 2023:
Memantine : Alzheimer's drug that aims to reduce cognitive impairment in Parkinson's.
Ganoderma/Lingzh : Mushrooms from traditional Chinese medicine are being studied for their potential to slow the progression of Parkinson's symptoms.
Buntanetap: Reduces the production of alpha-synuclein with the goal of improving motor symptoms of Parkinson's. "
Conclusion
In 2023, there are 89 trials with a completion date set for the end of the year. The increasing number of trials in the pipeline highlights the efforts of the Parkinson's community, and the resilience and determination to produce more rigorous science in the face of a global pandemic. There is much to be excited about, and we look forward to the updates the year will bring.
Overnight the FDA was approving clinical trials for treatments for the Corona virus. Why can’t it work on Parkinson's at the same pace
Clinical Trial Update 
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
